Skip to main content

Advertisement

Table 2 Unadjusted and adjusted linear regression analyses with flow-mediated vasodilation (ΔFMD) as the dependent variable

From: Rosuvastatin improves endothelial function in patients with inflammatory joint diseases, longitudinal associations with atherosclerosis and arteriosclerosis: results from the RORA-AS statin intervention study

   Unadjusted analyses Adjusted analysesa
  β (95 % CI) p value β (95 % CI) p value
Age −0.07 (−0.14, 0.01) 0.09  
Gender 0.38 (−0.89, 1.66) 0.55  
bDMARDs −1.07 (−2.31, 0.18) 0.09  
CRP Baseline −0.01 (−0.18, 0.16) 0.92 −0.02 (−0.18, 0.15) 0.86
Change 0.04 (−0.01, 0.09) 0.13 0.05 (−0.01, 0.10) 0.08
ESR Baseline −0.01 (−0.07, 0.05) 0.83 0.01 (−0.06, 0.08) 0.76
Change 0.04 (−0.02, 0.09) 0.18 0.04 (−0.01, 0.09) 0.15
DAS28 Baseline 0.24 (−0.82, 1.29) 0.66 0.29 (−0.73, 1.31) 0.57
Change 0.02 (−1.23, 1.27) 0.98 −0.25 (−1.43, 0.93) 0.67
ASDAS Baseline −0.01 (−0.40, 0.38) 0.96 0.08 (−0.53, 0.68) 0.78
Change 0.14 (−0.31, 0.58) 0.52 0.14 (−0.52, 0.81) 0.63
LDL-c Baseline 0.01 (0.62, 0.63) 0.98 −0.13 (−0.75, 0.50) 0.69
Change −0.17 (−0.91, 0.57) 0.65 −0.06 (−0.80, 0.68) 0.87
HDL-c Baseline −0.54 (−1.78, 0.70) 0.39 −0.26 (−1.70, 1.17) 0.72
Change −1.33 (−3.18, 0.52) 0.16 −1.43 (−3.28, 0.42) 0.13
AIx, change −0.09 (−0.18, 0.01) 0.06 −0.09 (−0.18, 0.00) < 0.05
aPWV, change −0.07 (−0.58, 0.43) 0.78 −0.14 (−0.66, 0.38) 0.59
CP height, change −3.51 (−5.28, −1.73) < 0.001 −3.10 (−4.95, −1.25) 0.001
c-IMT, change 3.55 (−4.51, 11.62) 0.38 3.96 (−4.77, 12.70) 0.37
Rosuvastatin dose 0.02 (−0.03, 0.07) 0.48 0.01 (−0.04, 0.06) 0.76
  1. bDMARDs biologic disease-modifying antirheumatic drugs, CRP C-reactive protein, ESR erythrocyte sedimentation rate, DAS28 disease activity score in 28 joints, ASDAS ankylosing spondylitis disease activity score, LDL-c low-density lipoprotein cholesterol, HDL-c high-density lipoprotein cholesterol, AIx augmentation index, aPWV aortic pulse wave velocity, CP carotid plaque, c-IMT carotid intima-media thickness
  2. aAdjusted for age, gender and use of bDMARDs